Opendata, web and dolomites

NO-META

Feasibility study of a NOvel METAbolic liquid biopsy for cancer therapy monitoring

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "NO-META" data sheet

The following table provides information about the project.

Coordinator
CYTOFIND DIAGNOSTICS BV 

Organization address
address: RIJKSSTRAATWEG 186
city: BEEK UBBERGEN
postcode: 6573 DG
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website http://www.cytofind.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-08-01   to  2016-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CYTOFIND DIAGNOSTICS BV NL (BEEK UBBERGEN) coordinator 50˙000.00

Map

 Project objective

Circulating Tumour Cells (CTCs) are strong indicators of the aggressiveness of metastatic cancer and there is strong evidence that CTCs are a reliable prognostic factor in patients with early-stage and metastatic breast cancer. Despite significant efforts, the detection and identification of CTCs in peripheral blood has proven difficult. The key technical challenge is posed by the rarity of tumour cells in blood, with estimates of just one CTC per ~1-10 million white blood cells per millilitre of blood. Up until now, there has been only one FDA-approved CTC enumeration system, CellSearch®, yet this state-of-the-art method suffers from severe limitations. There is an urgent need for new, alternative methods of CTCs enumeration and further characterization to fully realize the potential clinical benefits of CTC analysis. Lowering cost and speed of analysis coupled with ability to isolate CTC for further analysis would have a tremendous effect on diagnostics and treatment of cancer patients. It would provide novel means for early screening of individuals in a certain risk groups, elucidating most promising therapy options and following a chosen treatment and providing a cost-effective way to monitor patients in risk of relapse. Cytofind Diagnostics has developed a radically new method to count and isolate CTCs based on single cell determination of the anomalous metabolic properties of tumour cells (the so-called Warburg effect). Here, we wish to carefully analyze the potential impact of our technology on different parts of the oncology care cycle and establish which market is most suitable for the first introduction of our disruptive technology.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NO-META" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NO-META" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More